Kairos Pharma, LTD. - 10-Q Filing Summary
Business Context and Reporting Period
Kairos Pharma, LTD. (KAPA) is an early-stage clinical biopharmaceutical company focused on developing immunotherapy and cell therapy treatments for oncology. The company operates as a single reportable segment and has no approved products or revenue-generating operations to date. This filing covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,398) thousand | $(4,082) thousand | N/A |
| Operating Expenses | $(1,435) thousand | $(4,157) thousand | N/A |
| Cash and Cash Equivalents | N/A | N/A | $5,575 thousand |
| Shareholders' Equity | N/A | N/A | $7,664 thousand |
| Accumulated Deficit | N/A | N/A | $(12,897) thousand |
| Shares Outstanding | N/A | N/A | 20,821,353 |
Note: All financial figures are in thousands, except per share data and share counts.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly from $383 thousand in Q3 2024 to $1,435 thousand in Q3 2025. This was driven by a surge in Research and Development (R&D) expenses (from $14k to $608k) related to the initiation of Phase 2 clinical trials for prostate cancer, and increased General and Administrative (G&A) expenses (from $369k to $827k) due to vendor advance amortization and higher insurance costs.
- Net Loss: The net loss for the nine months ended September 30, 2025, was $4,082 thousand, compared to $1,623 thousand in the same period in 2024.
- Liquidity: Cash and cash equivalents increased from $1,272 thousand at December 31, 2024, to $5,575 thousand at September 30, 2025, primarily due to financing activities.
- Financing Activity: The company raised capital through a private placement (PIPE) and an Equity Line of Credit (ELOC). In the nine months ended Sept 30, 2025, the company received net proceeds of $3,058 thousand from the PIPE and $3,602 thousand from the ELOC.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current cash reserves are expected to fund operations for at least 12 months from the filing date. However, the company expects to continue incurring significant losses and will require additional capital to advance clinical trials and commercialize products.
- Capital Raising: The company relies on equity and debt financings. Future financing may result in substantial dilution to shareholders or contain restrictive covenants.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025. A material weakness persists regarding the lack of segregation of duties and insufficient review procedures due to the company's size.
- Subsequent Events:
- Entered into a $1,143 thousand amendment with Lonza for manufacturing support for a Phase 3 clinical trial.
- Granted 667,940 RSUs to executive officers and directors valued at $950 thousand.
- Executed novation agreements transferring license obligations from its subsidiary, Enviro Therapeutics, to Kairos Pharma.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity projection against current burn rates, considering the recent $1.1M Lonza commitment.
- Dilution Risk: Review the terms of the Equity Line of Credit (ELOC) with Helena Global and the outstanding 4.28 million warrants to assess potential future dilution.
- Internal Controls: Monitor remediation efforts for the material weakness in internal controls over financial reporting.
- Clinical Progress: Track the status of the Phase 2 prostate cancer trial and Phase 1 lung cancer trial, as these drive the majority of R&D spend.
- Vendor Advances: Confirm the amortization schedule and service delivery for the $1,057 thousand in remaining vendor advances.